Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tandem Diabetes Care filings document the company’s insulin delivery business, Nasdaq-listed common stock, operating results, governance matters, and capital structure. Recent 8-K reports furnish quarterly and annual financial results, guidance-related disclosures, and product or regulatory events tied to its diabetes technology portfolio.
The filing record also includes proxy materials for annual meeting voting, director elections, executive compensation, equity awards, and board committee matters. Material-event filings describe the company’s completed 0.00% convertible senior notes offering, related indenture terms, and FDA clearance for the SteadiSet wearable infusion set.
Tandem Diabetes Care Chair Emeritus Dick Allen reported routine equity compensation activity. On May 20, 2026, he received a grant of 10,220 restricted stock units (RSUs), each representing a contingent right to one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan. These RSUs will vest on the one-year anniversary of the grant, subject to plan terms.
On May 21, 2026, 8,759 previously granted RSUs vested and converted into the same number of common shares, increasing his directly held common stock to 28,146 shares after the transaction. A separate line shows 22,757 common shares held indirectly through the Allen Family Trust dated October 12, 1981.
Tandem Diabetes Care director Peyton R. Howell reported equity award activity. On May 21, 2026, 8,759 previously granted restricted stock units vested and were exercised into the same number of common shares, increasing direct holdings to 29,836 shares. On May 20, 2026, Howell also received a new grant of 10,220 restricted stock units under the company’s 2023 Long-Term Incentive Plan, which will vest on the one-year anniversary of the grant date.
Tandem Diabetes Care director Joao Paulo Falcao Malagueira increased his equity stake through stock-based compensation. On May 21, 2026, 8,759 restricted stock units granted on May 21, 2025 vested and converted into 8,759 shares of common stock. Following this vesting, he directly holds 22,458 common shares.
Separately, on May 20, 2026 he received a new grant of 10,220 restricted stock units under the company’s 2023 Long-Term Incentive Plan. These RSUs each represent a contingent right to receive one share of common stock or cash, and will vest on the one-year anniversary of the grant date.
Beaver Sandra reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care Inc. reported that director Sandra Beaver received a grant of 5,110 restricted stock units on May 20, 2026. Each RSU represents a contingent right to one share of common stock or cash, and the award will fully vest on the one-year anniversary of the grant date.
Tandem Diabetes Care director Rajwant Sodhi reported equity compensation activity. He received a grant of 10,220 restricted stock units (RSUs) on May 20, 2026, which will vest on the one-year anniversary of that date under the company’s 2023 Long-Term Incentive Plan.
Separately, 8,759 previously granted RSUs vested and converted into common shares, increasing his direct common stock holdings to 24,280 shares. These transactions reflect stock-based compensation and derivative exercises rather than open-market buying or selling.
Tandem Diabetes Care director Kathleen McGroddy-Goetz reported compensation-related equity activity. She received a grant of 10,220 restricted stock units (RSUs) on May 20, 2026, which will vest on the one-year anniversary of the grant under the company’s 2023 Long-Term Incentive Plan.
Separately, 8,759 RSUs granted on May 21, 2025 fully vested and converted into common shares. Following these transactions, she directly holds 26,612 shares of common stock. All reported moves are equity awards and RSU vesting, with no open-market buying or selling.
Tandem Diabetes Care director Rebecca B. Robertson received 10,220 restricted stock units (RSUs) on May 20, 2026 under the company’s 2023 Long-Term Incentive Plan. A prior grant of 8,759 RSUs from May 21, 2025 vested and converted into 8,759 common shares on its one-year anniversary, bringing her direct holdings to 22,542 shares.
Tandem Diabetes Care director Christopher J. Twomey reported equity compensation activity. On May 20, 2026, he received a grant of 10,220 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock or cash under the 2023 Long-Term Incentive Plan.
On May 21, 2026, a prior grant of 8,759 RSUs (awarded on May 21, 2025) fully vested and converted into common shares, increasing his directly held common stock to 24,434 shares. Additional common shares are held indirectly by the Chris J. Twomey and Rebecca J. Twomey Family Trust and by Twomey Family Investments, LLC, where he shares voting and investment power and disclaims beneficial ownership except for his proportionate pecuniary interest.
Tandem Diabetes Care director Myoungil Cha increased equity exposure through stock-based compensation. On May 21, 2026, 8,759 previously granted restricted stock units vested and converted into the same number of common shares under the company’s 2023 Long-Term Incentive Plan. On May 20, 2026, Cha also received a new award of 10,220 restricted stock units that will vest on the one-year anniversary of that grant, subject to plan terms. Following these transactions, Cha directly owns 22,458 shares of common stock.
Tandem Diabetes Care, Inc. reported results of its 2026 annual stockholder meeting and related governance changes. Stockholders approved amendments to the Amended and Restated Certificate of Incorporation to allow removal of directors with or without cause and to limit officer liability to the maximum extent permitted by Delaware law.
They also approved an amendment to the 2023 Long-Term Incentive Plan increasing the shares of common stock authorized for issuance under the plan by 3,260,000 shares. All nine director nominees were elected, executive compensation was approved on a non-binding advisory basis, and Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.
There were 68,504,233 shares of common stock outstanding on the March 23, 2026 record date, and 57,964,375 shares were present virtually or by proxy at the meeting, reflecting strong stockholder participation in the governance and compensation decisions.